| Property | Value |
|---|
|
?:abstract
|
-
We conducted a prospective study in healthcare workers (n=296) of the University Hospital of Lyon, France. Serum samples (n=296) collected six months after disease onset were tested using three commercial assays: the Wantai Ab assay detecting total antibodies against the receptor binding domain (RBD) of the S protein, the bioMerieux Vidas assay detecting IgG to the RBD and the Abbott Architect assay detecting IgG to the N protein. The neutralising antibody (NAb) titre was also determined for all samples with a virus neutralisation assay (VNA) using live virus. The positivity rate was 100% with the Wantai assay, 84.8% with the bioMerieux assay and 56.4% with the Abbott assay. Only 51% of HCWs were positive for the presence of NAb. Less than 10 % of HCWs NAb titer of 80. At a neutralising titer of 80, the area under the curves [IC 95%] was 0.71 [0.62-0.81], 0.75 [0.65-0.85] and 0.95 [0.92-0.97] for Wantai, Abbott and Vidas respectively. Commercial assays detecting antibodies against the N protein must not be used in long-term seroprevalence surveys while the Wantai assay could be very useful for this purpose. VNA should remain the gold standard to assess the protective antibody response, but some commercial assays could be useful for first-line screening of long-term presence of NAb.
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:doi
|
|
|
?:doi
|
-
10.1101/2020.12.08.20245811
|
|
?:license
|
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/a8c714bfbb2bc0fe50323730b94b473feee84e3a.json
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:sha_id
|
|
|
?:source
|
|
|
?:title
|
-
Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by virus neutralisation and commercial assays
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}